Brokerages Set Bausch Health Companies Inc. (NYSE:BHC) Price Target at $7.75

Bausch Health Companies Inc. (NYSE:BHC) has been assigned an average rating of “Hold” from the seven ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $7.75.

A number of research analysts have commented on the company. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Evercore ISI raised Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th. Royal Bank of Canada increased their price objective on shares of Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Friday, November 1st. Finally, Jefferies Financial Group reduced their target price on shares of Bausch Health Companies from $13.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, August 7th.

Insider Transactions at Bausch Health Companies

In other Bausch Health Companies news, EVP Seana Carson sold 13,370 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $6.21, for a total transaction of $83,027.70. Following the sale, the executive vice president now directly owns 435,198 shares of the company’s stock, valued at approximately $2,702,579.58. This represents a 2.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 8.12% of the company’s stock.

Hedge Funds Weigh In On Bausch Health Companies

A number of large investors have recently bought and sold shares of BHC. Goldentree Asset Management LP grew its stake in Bausch Health Companies by 31.0% during the 3rd quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company’s stock worth $239,552,000 after buying an additional 6,958,717 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Bausch Health Companies by 1.0% during the first quarter. Vanguard Group Inc. now owns 11,713,993 shares of the company’s stock worth $124,285,000 after acquiring an additional 114,862 shares during the last quarter. Bank of Montreal Can lifted its position in Bausch Health Companies by 234.0% in the 3rd quarter. Bank of Montreal Can now owns 3,833,179 shares of the company’s stock valued at $31,598,000 after purchasing an additional 2,685,675 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Bausch Health Companies by 12.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,165,512 shares of the company’s stock valued at $22,063,000 after purchasing an additional 341,936 shares during the period. Finally, Mackenzie Financial Corp boosted its position in shares of Bausch Health Companies by 111.0% during the second quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company’s stock worth $16,612,000 after buying an additional 1,252,834 shares during the period. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Stock Performance

BHC opened at $8.37 on Wednesday. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $11.46. The firm has a 50 day moving average price of $8.41 and a 200 day moving average price of $7.14. The company has a market cap of $3.01 billion, a PE ratio of -17.44 and a beta of 0.74.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The company had revenue of $2.51 billion during the quarter, compared to analyst estimates of $2.42 billion. During the same quarter in the prior year, the business earned $1.03 earnings per share. The business’s quarterly revenue was up 12.2% compared to the same quarter last year. On average, sell-side analysts predict that Bausch Health Companies will post 3.74 earnings per share for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.